Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
about
Neuroendocrine differentiation in prostate cancerEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderSRC: marker or actor in prostate cancer aggressivenessDasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinasesPrognostic role of neuroendocrine differentiation in prostate cancer, putting together the pieces of the puzzle.Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growthEvolving role of bone biomarkers in castration-resistant prostate cancer.SRC: a century of science brought to the clinic.Novel dual Src/Abl inhibitors for hematologic and solid malignancies.Molecular pathways and targets in prostate cancerMinireview: Alternative activation pathways for the androgen receptor in prostate cancer.Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?Autophagy as a modulator and target in prostate cancer.Novel role of androgens in mitochondrial fission and apoptosisLin28 promotes growth of prostate cancer cells and activates the androgen receptorBrachyury as a potential modulator of androgen receptor activity and a key player in therapy resistance in prostate cancer.Src kinase inhibitors: an emerging therapeutic treatment option for prostate cancer.Targeting tyrosine kinases and autophagy in prostate cancer.Expression and function of gastrin-releasing peptide (GRP) in normal and cancerous urological tissues.Midkine is associated with neuroendocrine differentiation in castration-resistant prostate cancer.Emerging drugs for the treatment of bone metastasis.miR-124 and Androgen Receptor Signaling Inhibitors Repress Prostate Cancer Growth by Downregulating Androgen Receptor Splice Variants, EZH2, and Src.TMPRSS2:ERG blocks neuroendocrine and luminal cell differentiation to maintain prostate cancer proliferation.Interleukin-6 induces neuroendocrine differentiation (NED) through suppression of RE-1 silencing transcription factor (REST).Mitochondrial determinants of cancer health disparities.Simultaneous targeting of Src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration.Castration-resistant prostate cancer: targeted therapies and individualized treatmentAberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.Activation of Rac1 is closely related to androgen-independent cell proliferation of prostate cancer cells both in vitro and in vivo.Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors.GRPR antagonists for prostate cancer--prospects and caveats.
P2860
Q24657547-F8F8EF80-01A0-4911-A481-1F1DD1784749Q26859114-B6A4FBB3-A4D4-45CD-87D1-698802A0D85BQ27012541-E9DC3A70-8E1C-4AD1-B060-6FC109754C3FQ30433918-D950560D-CA55-4D7F-A2E2-E03900DECDDBQ33356928-C99751A1-862A-45EF-91BE-6D6B044FFED0Q33925625-801171CA-3D85-41DA-AA87-3EF932D91F27Q34023877-6D319B15-5A9C-4285-BD30-D8F2068A63B0Q34041298-C2E5BF51-F11C-4FF0-97A4-A1BEA44B514BQ34121339-E9E709AC-99FB-49B3-BED6-E41A85524D5CQ34365632-9D9D6BAF-891D-4F1D-B0D1-7E4D12F66B95Q35001285-7C6D7A8F-80BA-4CB0-96B6-CB896EAA6E62Q35141115-E2A7D58E-E23C-463C-92B3-C592CC4B92BBQ35557084-25B691FB-B68A-4BF3-85B1-D11FB85D63CBQ35791838-EB51F990-F2C7-4282-B28E-6909DBF46C3EQ36986508-338FBF73-3C8F-4346-805E-872178A123B0Q37301697-E9399FC6-C3B9-418E-9E63-AA006E5A2516Q37724378-CAB075A7-0963-47F6-A6AD-CDC2F329E2A1Q37847052-B67B9D34-17EB-4553-B30C-B5CA34F8839DQ38217450-7C1462E4-B320-4478-BF8B-1C452BCFFA69Q38399930-12E452DD-901C-4E07-9CD7-DD44BCF5AE43Q38538263-FDA602E5-FCFC-46A4-BC14-6474E3471E01Q38819163-86C469FD-5EAD-46D6-AB76-37C0052387C4Q38952586-1848BEF1-89BB-4DB1-917E-FF9A360CC7D6Q38995864-752A5BFC-0E18-4936-B5CE-E1C06EC314B6Q39294200-94055714-56A1-4B31-A924-BE73235AF1D2Q39500289-E97CADDD-3FD0-4CCA-8726-C37FAADD3849Q39511732-8BC41F8E-C417-46D6-924D-6D74A7CFA36BQ39715232-4768C55B-3975-4D10-B751-E820E9EC7787Q39732250-B61BAACC-72B6-421F-9CB2-68AD386A2EDEQ41935042-04C4CB35-4A3F-4CF0-B148-A21B38686892Q50881807-C0EC0729-6116-4AF5-A5A0-45E8E5C2352E
P2860
Aberrant activation of androgen receptor in a new neuropeptide-autocrine model of androgen-insensitive prostate cancer.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Aberrant activation of androge ...... n-insensitive prostate cancer.
@en
Aberrant activation of androge ...... n-insensitive prostate cancer.
@nl
type
label
Aberrant activation of androge ...... n-insensitive prostate cancer.
@en
Aberrant activation of androge ...... n-insensitive prostate cancer.
@nl
prefLabel
Aberrant activation of androge ...... n-insensitive prostate cancer.
@en
Aberrant activation of androge ...... n-insensitive prostate cancer.
@nl
P2093
P2860
P1433
P1476
Aberrant activation of androge ...... n-insensitive prostate cancer.
@en
P2093
Alexander D Borowsky
Christopher P Evans
Hsing-Jien Kung
J Erik Busby
Joon-ha Ok
Joy C Yang
P2860
P304
P356
10.1158/0008-5472.CAN-08-0442
P407
P577
2009-01-01T00:00:00Z